MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,773.95
+0.66%
NASDAQ 100
$31,076.44
+0.87%
DOW JONES
$51,268.00
+0.18%
NASDAQ Composite
$27,477.31
+1.05%
RUSSELL 2000
$2,833.80
+0.66%
CBOE VIX
$15.52
+1.37%
Sector Heatmap
Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%
KROS — Keros Therapeutics, Inc. Common Stock
NasdaqKeros Therapeutics, Inc. Common Stock
$11.52
+0.16(+1.41%)
- O
- 11.38
- H
- 11.56
- L
- 11.07
- V
- 132.41K
⏱️ End-of-day dataAs of Oct 5, 2026
KROS — Latest News & Headlines
7 StoriesKeros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Average Target Price of $20.50 According to Brokerages - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Average Target Price of $20.50 According to Brokerages MarketBeat
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD - Yahoo Finance
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD Yahoo Finance
Keros Therapeutics Expects $20 Million Milestone Payment After First Patient Dosed in Takeda’s ELRiSE MF Phase 3 Trial - Quiver Quantitative
Keros Therapeutics Expects $20 Million Milestone Payment After First Patient Dosed in Takeda’s ELRiSE MF Phase 3 Trial Quiver Quantitative
Price-Driven Insight from (KROS) for Rule-Based Strategy - Stock Traders Daily
Price-Driven Insight from (KROS) for Rule-Based Strategy Stock Traders Daily
How (KROS) Movements Inform Risk Allocation Models - Stock Traders Daily
How (KROS) Movements Inform Risk Allocation Models Stock Traders Daily
Keros Therapeutics earns milestone for Phase 3 myelofibrosis trial - TipRanks
Keros Therapeutics earns milestone for Phase 3 myelofibrosis trial TipRanks
Keros Begins Phase 2 Rinvatercept Trial in DMD - TipRanks
Keros Begins Phase 2 Rinvatercept Trial in DMD TipRanks